Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Inclusion Criteria: * Histologically confirmed diagnosis of melanoma with measurable disease * Patients with stage IV or unresectable advanced melanoma * Age at least 16 years. * ECOG performance status of 0-1 * Life expectancy \> 3 months * Adequate major organ function to tolerate therapy, as defined by: * Total bilirubin 2.0 mg/dL. * Creatinine 1.8 mg/dL. * WBC 3,000/mm3. * Platelet count 100,000/mm3. * Patients 50 years of age with one or more cardiac risk factors must demonstrate normal exercise stress test, stress thallium test, or comparable cardiac ischemia evaluation * Left ventricular ejection fraction \> 40% * Women of childbearing age must agree to use barrier method birth control and demonstrate a negative pregnancy test prior to initiation of protocol therapy. Periodic negative urine pregnancy tests will also be required. * Patients must give written informed consent Exclusion Criteria: * No prior HD- IL-2 for stage IV/unresectable advanced disease. Prior low dose IL-2 is allowed. * No more than 2 prior chemotherapy regimens are allowed. * No active CNS metastases. Treated CNS metastases without recurrence or progression for \> 8 weeks are allowed. * No concurrent use of systemic corticosteroids * Pregnant and/or lactating are excluded * No concurrent antineoplastic treatments, including chemotherapy, biologic response modifiers, radiation, vaccines, or other experimental therapies. * No treatment for melanoma within the previous 4 weeks.